Stage of chronic kidney disease and severity of coronary heart disease manifestation

Bibliography

• Chronic Kidney Disease (CKD) data. National Kidney Foundation. Available from: http://www.kidney.org/kidneyDisease/ckd/index.cfm [Last accessed 31 December 2011]
   Google Scholar
• Iseki K. Chronic kidney disease in Japan. Intern Med 2008;47:681-9
   PubMed Web of Science ®Google Scholar
• Go AS, Chertow GM, Fan D, Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305
   PubMed Web of Science ®Google Scholar
• Nakamura K, Okamura T, Hayakawa T, NIPPON DATA90 Research Group. Chronic kidney disease is a risk factor for cardiovascular death in a community-based population in Japan: NIPPON DATA90. Circ J 2006;70:954-9
   PubMedGoogle Scholar
• Athyros VG, Mikhailidis DP, Liberopoulos EN, Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) Study. Nephrol Dial Transplant 2007;22:118-27
   PubMed Web of Science ®Google Scholar
• Athyros VG, Papageorgiou AA, Elisaf M, Mikhailidis DP; GREACE Study Collaborative Group. Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin 2003;19:615-17
   PubMed Web of Science ®Google Scholar
• Shepherd J, Kastelein JJ, Bittner V, Treating to New Targets Investigators. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2007;2:1131-9
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, CARDS Investigators. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 2009;54:810-19
   PubMed Web of Science ®Google Scholar
• Pun PH, Smarz TR, Honeycutt EF, Chronic kidney disease is associated with increased risk of sudden cardiac death among patients with coronary artery disease. Kidney Int 2009;76:652-8
   PubMed Web of Science ®Google Scholar
• Genest J, McPherson R, Frohlich J, 2009 Canadian cardiovascular society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. Can J Cardiol 2009;25:567-79
   PubMed Web of Science ®Google Scholar
• Reiner Z, Catapano AL, De Backer G, ESC/EAS Guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818
   PubMed Web of Science ®Google Scholar
• Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Should chronic kidney disease be considered as a coronary heart disease equivalent? Curr Vasc Pharmacol 2011; In press
   Google Scholar
• Zoccali C. The burden of cardiovascular disease in patients with chronic kidney disease and in end-stage renal disease. Contrib Nephrol 2008;161:63-7
   PubMedGoogle Scholar
• Go AS, Bansal N, Chandra M, ADVANCE Study Investigators. Chronic kidney disease and risk for presenting with acute myocardial infarction versus stable exertional angina in adults with coronary heart disease. J Am Coll Cardiol 2011;58:1600-7
   PubMed Web of Science ®Google Scholar
• Athyros VG, Papageorgiou AA, Mercouris BR, Treatment with atorvastatin to the National cholesterol educational program goal versus ‘usual’ care in secondary coronary heart disease prevention. The Greek atorvastatin and coronary-heart-disease evaluation (GREACE) study. Curr Med Res Opin 2002;18:220-8
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Papageorgiou AA, The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004;57:728-34
   PubMed Web of Science ®Google Scholar
• Athyros VG, Ganotakis E, Kolovou G, For the Assessing the Treatment Effect in Metabolic Syndrome without Perceptible Diabetes (ATTEMPT) Collaborative Group. Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT). A prospective-randomized study in middle aged men and women. Curr Vasc Pharmacol 2011;9:647-57
   PubMed Web of Science ®Google Scholar
• Athyros VG, Karagiannis A, Ganotakis ES, For the Assessing the Treatment Effect in Metabolic Syndrome without Perceptible Diabetes (ATTEMPT) Collaborative Group. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin 2011;27:1659-68
   PubMed Web of Science ®Google Scholar
• Go AS, Iribarren C, Chandra M, Atherosclerotic Disease, Vascular Function and Genetic Epidemiology (ADVANCE) Study. Statin and beta-blocker therapy and the initial presentation of coronary heart disease. Ann Intern Med 2006;144:229-38
   PubMedGoogle Scholar
• Toso A, Leoncini M, Maioli M, Short-term high-dose atorvastatin for periprocedural myocardial infarction prevention in patients with renal dysfunction. J Cardiovasc Med (Hagerstown) 2011;12:318-21
   PubMedGoogle Scholar
• Charytan DM, Kuntz RE, Garshick M, Location of acute coronary artery thromboses in patients with and without chronic kidney disease. Kidney Int 2009;75:80-7
   PubMed Web of Science ®Google Scholar
• Kono K, Fujii H, Miyoshi N, Coronary plaque morphology using virtual histology-intravascular ultrasound analysis in hemodialysis patients. Ther Apher Dial 2011;15:44-50
   PubMedGoogle Scholar
• Athyros VG, Karagiannis A, Kakafika A, Statins and renal function. Is the compound and dose making a difference? Nephrol Dial Transplant 2007;22:963-4
   PubMed Web of Science ®Google Scholar
• Baigent C, Landray MJ, Reith C, SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-92
   PubMed Web of Science ®Google Scholar
• Athyros VG, Katsiki N, Tziomalos K, Preventing cardio-renal syndrome rather than treating it: could statins play a role? Open Cardiovasc Med J 2011;5:226-30
   PubMedGoogle Scholar